Literature DB >> 7598720

Mutational analysis of cysteine residues within the extracellular domains of the human vasoactive intestinal peptide (VIP) 1 receptor identifies seven mutants that are defective in VIP binding.

P Gaudin1, A Couvineau, J J Maoret, C Rouyer-Fessard, M Laburthe.   

Abstract

We have used site-directed mutagenesis to investigate the requirement of cysteine residues in the extracellular domains of the human VIP 1 receptor for binding VIP. Cys37, Cys50, Cys63, Cys72, Cys86, Cys105 and Cys122 (N-terminal extracellular domain), Cys208 and Cys215 (second extracellular loop) and Cys288 (third extracellular loop) were mutated into glycine, and mutated cDNAs transfected into Cos-7 cells. It appeared that mutants C50G, C63G, C72G, C86G, C105G, C122G, and C288G did not bind VIP whereas mutants C37G, C208G and C215G bound VIP with the same dissociation constant (#0.5 nM) as the wild-type receptor. All mutated receptor proteins were synthesized by Cos-7 cells (Western blot) and delivered at the plasma membrane level (confocal microscopy). The fact that C208G and C215G mutants retained a complete binding activity while the C288G mutant was inactive does not suggest the presence of a functionally relevant disulfide bond between the second and third extracellular loop of the human VIP receptor contrary to what has been shown in several other heptahelical receptors. It is also concluded that the six crucial cysteine residues, e.g., Cys50, Cys63, Cys72, Cys86, Cys105 and Cys122 in the N-terminal extracellular domain, may be functionally important by forming intramolecular disulfide bonds which help to maintain the topology for ligand binding in human VIP 1 receptors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7598720     DOI: 10.1006/bbrc.1995.1897

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

Review 1.  Structural and functional insights into the juxtamembranous amino-terminal tail and extracellular loop regions of class B GPCRs.

Authors:  M Dong; C Koole; D Wootten; P M Sexton; L J Miller
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

2.  Vasoactive intestinal peptide induces proliferation of human hepatocytes.

Authors:  M E M S Khedr; A M Abdelmotelb; T A Bedwell; A Shtaya; M N Alzoubi; M Abu Hilal; S I Khakoo
Journal:  Cell Prolif       Date:  2018-07-20       Impact factor: 6.831

3.  The human vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor 1 (VPAC1) promoter: characterization and role in receptor expression during enterocytic differentiation of the colon cancer cell line Caco-2Cl.20.

Authors:  A Couvineau; J J Maoret; C Rouyer-Fessard; I Carrero; M Laburthe
Journal:  Biochem J       Date:  2000-05-01       Impact factor: 3.857

4.  Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS.

Authors:  Chaohong Sun; Danying Song; Rachel A Davis-Taber; Leo W Barrett; Victoria E Scott; Paul L Richardson; Ana Pereda-Lopez; Marie E Uchic; Larry R Solomon; Marc R Lake; Karl A Walter; Philip J Hajduk; Edward T Olejniczak
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

5.  Pharmacological characterization of human incretin receptor missense variants.

Authors:  Jean-Philippe Fortin; Jonathan C Schroeder; Yuantee Zhu; Martin Beinborn; Alan S Kopin
Journal:  J Pharmacol Exp Ther       Date:  2009-10-19       Impact factor: 4.030

6.  The palmitoylation of the N-terminal extracellular Cys37 mediates the nuclear translocation of VPAC1 contributing to its anti-apoptotic activity.

Authors:  Rongjie Yu; Hongyu Liu; Xinhe Peng; Yue Cui; Suqin Song; Like Wang; Huahua Zhang; An Hong; Tianhong Zhou
Journal:  Oncotarget       Date:  2017-06-27

7.  A new neuropeptide insect parathyroid hormone iPTH in the red flour beetle Tribolium castaneum.

Authors:  Jia Xie; Ming Sang; Xiaowen Song; Sisi Zhang; Donghun Kim; Jan A Veenstra; Yoonseong Park; Bin Li
Journal:  PLoS Genet       Date:  2020-05-04       Impact factor: 5.917

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.